Patents by Inventor Steven R. Schow

Steven R. Schow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190031674
    Abstract: The present disclosure provides methods for purifying a solution comprising cantharidin and cantharidin-associated impurities. A method to purify the solution can comprise recrystallization or sublimation, for example. The purified cantharidin can be analyzed using a detection method comprising a stationary phase and one or more mobile phases.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 31, 2019
    Applicant: Verrica Pharmaceuticals, Inc.
    Inventors: Matthew Davidson, Garry Southan, Steven R. Schow, Robert Moore
  • Publication number: 20190002474
    Abstract: The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.
    Type: Application
    Filed: December 17, 2015
    Publication date: January 3, 2019
    Inventors: Matthew Davidson, Steven R. Schow
  • Publication number: 20140315812
    Abstract: Provided herein is an amorphous form of a pharmaceutically acceptable salt of ezatiostat, for example, ezatiostat hydrochloride, compositions, uses and methods of preparation thereof.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 23, 2014
    Inventor: Steven R. Schow
  • Patent number: 8361971
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: January 29, 2013
    Assignee: Telik, Inc.
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • Patent number: 8334266
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2012
    Assignee: Telik, Inc.
    Inventors: William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
  • Publication number: 20120238772
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 20, 2012
    Inventors: William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernández Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
  • Patent number: 8198247
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: June 12, 2012
    Assignee: Telik, Inc.
    Inventors: William A. Boulanger, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Harold Meckler, Steven R. Schow, Pavel E. Zhichkin
  • Publication number: 20120021054
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Application
    Filed: September 27, 2011
    Publication date: January 26, 2012
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • Patent number: 8093231
    Abstract: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: January 10, 2012
    Assignee: Telik, Inc.
    Inventors: David R. Allen, Wenli Ma, Brian T. Peterson, Louise Robinson, Steven R. Schow, Songyuan Shi, Reyna J. Simon, Kevin T. Weber, Michael M. Wick
  • Publication number: 20110301088
    Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.
    Type: Application
    Filed: March 4, 2011
    Publication date: December 8, 2011
    Inventors: Stephan D. Parent, Steven R. Schow
  • Publication number: 20110300215
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Application
    Filed: March 29, 2011
    Publication date: December 8, 2011
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • Publication number: 20080159980
    Abstract: A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST- activated anticancer compound (including chemotherapy; molecular targeted therapy; biologic therapy; and radiotherapy, used as monotherapy or in combination). Pharmaceutical compositions, products, and kits for the method. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. A method of potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of U.
    Type: Application
    Filed: October 15, 2007
    Publication date: July 3, 2008
    Inventors: Hua Xu, Gail L. Brown, Steven R. Schow, James G. Keck
  • Patent number: 7262182
    Abstract: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: August 28, 2007
    Assignee: Telik, Inc.
    Inventors: Louise Robinson, Steven R. Schow, Songyuan Shi
  • Patent number: 7192918
    Abstract: Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation, are disclosed. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: March 20, 2007
    Assignee: Telik, Inc.
    Inventors: Steven R. Schow, Natalia Aurrecoechea
  • Patent number: 7129215
    Abstract: Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: October 31, 2006
    Assignee: Telik, Inc.
    Inventors: Natalia Aurrecoechea, Andrew B. Kelson, Robert W. Macsata, Louise Robinson, Anthony J. Sanchez, Nicholas M. Santiago, Steven R. Schow, Reyna J. Simon
  • Patent number: 7071231
    Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 4, 2006
    Assignee: Telik, Inc.
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
  • Patent number: 7029695
    Abstract: Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: April 18, 2006
    Assignee: Telik, Inc.
    Inventors: Thomas Redelmeier, Lawrence M. Kauvar, Robert T. Lum, Matthew H. Lyttle, Robert W. Macsata, Steven R. Schow, Hugo O. Villar, Michael R. Kozlowski
  • Patent number: 6794390
    Abstract: A compound having the formula: wherein: R1 is —X—R1′; in which R1′ is lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or heterocyclic, and X is —NH—; R2 is isopropyl; and R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino or R4 and R5 are both lower alkyl substituted with one, two or three groups chosen from hydroxy and amino, or an acid addition salt or cationic salt thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: September 21, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow
  • Patent number: 6790958
    Abstract: Compounds of the following formula are provided: wherein: R1 is —X—R1′; in which R1′ is alkyl, cycloalkyl, aryl, aralkyl, hetaryl, or heterocyclyl, all of which are optionally substituted; X is —NH; R2 is optionally substituted lower alkyl; and R3 is —NR4R5; in which R4 and R5 independently are hydrogen or lower alkyl optionally substituted by hydroxy or amino; or acid addition salts or cationic salts thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: September 14, 2004
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow, Jeffery A. Zablocki, Prabbha Ibrahim
  • Patent number: 6781000
    Abstract: &agr;-ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having the following formula: wherein X2 is Ar or Ar—X3 wherein X3 is is —C═O, or —CH2CO—, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls; R1, and R2 are each individually selected from the side chains of the known natural &agr;-amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl; X1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and wherein X4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and R3 is selected from the known natural &agr;-amino acids, unnatural amino acids
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: August 24, 2004
    Assignee: CV Theurapeutics, Inc.
    Inventors: Lisa Wang, Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Michael M Wick